Merck (MRK) Reports EMA Validation of Type II Variation for KEYTRUDA (pembrolizumab) in Combination with Pemetrexed (ALIMTA) and Platinum Chemotherapy
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that following validation by the European ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
